Levobupivacaine Altan (Levobupivacaine)

Levobupivacaine acts by reversibly inhibiting voltage‑gated sodium channels on neuronal membranes. This blockade prevents sodium influx required for depolarization, thereby stopping the propagation of nerve impulses. The result is a reversible loss of sensation in the area where the drug is administered, while motor function may be preserved at appropriate concentrations.

The specific dose of Levobupivacaine Altan is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Dosage regimens are individualized and must follow local medical guidelines and the product’s prescribing information.

Safety data for Levobupivacaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur when clearly indicated and after careful risk‑benefit assessment by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and assist with any required import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and generally offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents block sodium channels, but Levobupivacaine’s stereochemistry provides an improved safety profile, especially in high‑dose or continuous infusion settings.

Levobupivacaine Altan should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Ensure that the vial or ampoule remains sealed until use to maintain sterility.

Levobupivacaine is administered by a qualified healthcare professional via epidural, intrathecal, or infiltration techniques. The drug is supplied as a sterile solution for injection and is injected directly into the intended anatomical space under aseptic conditions, following the dosing instructions provided by the prescriber.

Serious risks include cardiovascular toxicity such as arrhythmias, cardiac arrest, and severe hypotension, as well as central nervous system toxicity manifesting as seizures or prolonged motor block. Rare allergic reactions and methemoglobinemia may also occur. Immediate medical attention is required if any of these events are suspected.

Levobupivacaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with significant hepatic impairment where drug metabolism may be compromised. It is also contraindicated when inadvertent intravascular injection is likely.